A new potential nano-oncological therapy based on polyamino acid nanocapsules
Por favor, use este identificador para citas ou ligazóns a este ítem:
http://hdl.handle.net/10347/16975
Ficheiros no ítem
Metadatos do ítem
Título: | A new potential nano-oncological therapy based on polyamino acid nanocapsules |
Autor/a: | Gonzalo, Teresa Lollo, Giovanna García-Fuentes, Marcos Torres, Dolores Correa, Juan Riguera Vega, Ricardo Fernández Megía, Eduardo Calvo, Pilar Avilés, Pablo Guillén, Maria José Alonso Fernández, María José |
Centro/Departamento: | Universidade de Santiago de Compostela. Centro de Investigación en Química Biolóxica e Materiais Moleculares Universidade de Santiago de Compostela. Centro de Investigación en Medicina Molecular e Enfermidades Crónicas Universidade de Santiago de Compostela. Departamento de Farmacia e Tecnoloxía Farmacéutica Universidade de Santiago de Compostela. Departamento de Química Orgánica |
Palabras chave: | Nanomedicines | Long-circulating nanocarriers | Nanocapsules | Polyglutamic acid | Cancer | |
Data: | 2013-07 |
Editor: | Elsevier |
Cita bibliográfica: | Gonzalo, T., Lollo, G., Garcia-Fuentes, M., Torres, D., Correa, J., & Riguera, R. et al. (2013). A new potential nano-oncological therapy based on polyamino acid nanocapsules. Journal Of Controlled Release, 169(1-2), 10-16. doi: 10.1016/j.jconrel.2013.03.037 |
Resumo: | A critical objective in cancer therapy is to reduce the systemic toxicity through the modification of the biodistribution of anticancer drugs. Herein, we disclose a new biodegradable nanocarrier, polyglutamic acid (PGA) nanocapsules, and present the in vivo pharmacokinetics/toxicity proof-of-concept for the anticancer drug plitidepsin. These novel nanocapsules were prepared using a modified solvent displacement technique where the polyamino acid was electrostatically deposited onto the lipid core. The nanocapsules exhibited an average size of 200 nm, a negative zeta potential and a great capacity for the encapsulation of plitidepsin (encapsulation efficiency above 90%). In addition, the nanocapsules could be freeze-dried and showed an adequate stability profile upon storage. Finally, the in vivo proof-of-concept studies performed in mice indicated that the encapsulation provided the drug with a prolonged blood circulation and a significantly reduced toxicity. In fact, the maximum tolerated dose of the nanoencapsulated drug was more than 3 times that of the reference formulation (Cremophor® EL plitidepsin solution). Overall, beyond the value of this specific formulation, the work reported here represents the evidence of the potential of polyamino acid nanocapsules in nano-oncological therapy |
Versión do editor: | https://doi.org/10.1016/j.jconrel.2013.03.037 |
URI: | http://hdl.handle.net/10347/16975 |
DOI: | 10.1016/j.jconrel.2013.03.037 |
ISSN: | 0168-3659 |
Dereitos: | © 2013 Elsevier B.V. This manuscript version is made available under the CC-BY-NC-ND 4.0 license (http:// creativecommons.org/licenses/by-nc-nd/4.0/) |
Coleccións
-
- CIMUS-Artigos [249]
- CIQUS-Artigos [475]
- FTF-Artigos [274]
- QO-Artigos [436]